1. Home
  2. SNGX vs PPBT Comparison

SNGX vs PPBT Comparison

Compare SNGX & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNGX
  • PPBT
  • Stock Information
  • Founded
  • SNGX 1987
  • PPBT 2010
  • Country
  • SNGX United States
  • PPBT Israel
  • Employees
  • SNGX N/A
  • PPBT N/A
  • Industry
  • SNGX Biotechnology: Pharmaceutical Preparations
  • PPBT Biotechnology: Pharmaceutical Preparations
  • Sector
  • SNGX Health Care
  • PPBT Health Care
  • Exchange
  • SNGX Nasdaq
  • PPBT Nasdaq
  • Market Cap
  • SNGX 6.5M
  • PPBT 6.2M
  • IPO Year
  • SNGX 1987
  • PPBT N/A
  • Fundamental
  • Price
  • SNGX $1.36
  • PPBT $2.60
  • Analyst Decision
  • SNGX Strong Buy
  • PPBT Strong Buy
  • Analyst Count
  • SNGX 1
  • PPBT 1
  • Target Price
  • SNGX $6.00
  • PPBT $33.00
  • AVG Volume (30 Days)
  • SNGX 2.7M
  • PPBT 16.5K
  • Earning Date
  • SNGX 08-08-2025
  • PPBT 08-15-2025
  • Dividend Yield
  • SNGX N/A
  • PPBT N/A
  • EPS Growth
  • SNGX N/A
  • PPBT N/A
  • EPS
  • SNGX N/A
  • PPBT N/A
  • Revenue
  • SNGX $2,342.00
  • PPBT N/A
  • Revenue This Year
  • SNGX N/A
  • PPBT N/A
  • Revenue Next Year
  • SNGX N/A
  • PPBT N/A
  • P/E Ratio
  • SNGX N/A
  • PPBT N/A
  • Revenue Growth
  • SNGX N/A
  • PPBT N/A
  • 52 Week Low
  • SNGX $1.09
  • PPBT $2.00
  • 52 Week High
  • SNGX $7.20
  • PPBT $13.95
  • Technical
  • Relative Strength Index (RSI)
  • SNGX 44.21
  • PPBT 60.83
  • Support Level
  • SNGX $1.24
  • PPBT $2.35
  • Resistance Level
  • SNGX $1.40
  • PPBT $2.58
  • Average True Range (ATR)
  • SNGX 0.14
  • PPBT 0.12
  • MACD
  • SNGX 0.03
  • PPBT 0.02
  • Stochastic Oscillator
  • SNGX 34.18
  • PPBT 100.00

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

About PPBT Purple Biotech Ltd.

Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.

Share on Social Networks: